Ginkgo Bioworks announced the successful completion of the gene therapy collaboration they announced with Biogen in May 2021. Together, the companies aimed to redefine the industry standard for manufacturing recombinant adeno-associated virus (AAV)-based vectors. The collaboration achieved their goals of enhancing the AAV production titers of Biogen's gene therapy manufacturing processes.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8601 USD | +10.60% | -0.55% | -49.11% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-49.11% | 1.72B | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- DNA Stock
- News Ginkgo Bioworks Holdings, Inc.
- Ginkgo Bioworks Completes Program with Biogen to Boost Productivity of Gene Therapy Manufacturing Platform